Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Chemsyn Pharm Co has the GF Score of 56, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Zhejiang Chemsyn Pharm Co
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Zhejiang Chemsyn Pharm Co (BJSE:920656) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Zhejiang Chemsyn Pharm Co GF Score Related Terms
BJSE:920656 vs UNH, CVS, ELV: GF Score Comparison
For the Healthcare Plans subindustry, Zhejiang Chemsyn Pharm Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Chemsyn Pharm Co GF Score vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Zhejiang Chemsyn Pharm Co's GF Score distribution charts can be found below:
* The bar in red indicates where Zhejiang Chemsyn Pharm Co's GF Score falls into.
Zhejiang Chemsyn Pharm Co (BJSE:920656) has a GF Score of 56 as of Sep. 12, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Zhejiang Chemsyn Pharm Co and its competitors. This is 56% above median its historical median of 36.00. Over the past decade, Zhejiang Chemsyn Pharm Co's GF Score has ranged from 28.00 to 61.00.
Is Zhejiang Chemsyn Pharm Co's GF Score too high?
Zhejiang Chemsyn Pharm Co's current GF Score of 56 is 56% above median its 10-year median of 36.00. Over the past 10 years, this metric has ranged from a low of 28.00 to a high of 61.00. Overall, Zhejiang Chemsyn Pharm Co has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Chemsyn Pharm Co's GF Score compare to UNH and CVS?
Zhejiang Chemsyn Pharm Co's GF Score of 56 can be compared against companies in the Healthcare Plans industry. Historically, Zhejiang Chemsyn Pharm Co's own GF Score has ranged from 28.00 to 61.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Healthcare Plans company?
A good GF Score depends on the Healthcare Plans industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Zhejiang Chemsyn Pharm Co and its competitors. Zhejiang Chemsyn Pharm Co's current GF Score is 56, which is 56% above median its own 10-year median of 36.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Chemsyn Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Chemsyn Pharm Co (BJSE:920656) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥19.02, compared to a current price of ¥14.28 — trading 24.9% below its estimated fair value. The current GF Score is 56, which is 56% above median its 10-year median of 36.00. Zhejiang Chemsyn Pharm Co's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Zhejiang Chemsyn Pharm Co (BJSE:920656), the current GF Score is 56 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Chemsyn Pharm Co (BJSE:920656) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Chemsyn Pharm Co stock appears to be undervalued.
The current stock price of ¥14.28 is trading 24.9% below its estimated GF Value™ of ¥19.02.
GuruFocus considers Zhejiang Chemsyn Pharm Co to be Modestly Undervalued.
Key valuation signals for BJSE:920656:
GF Score: 56 (56% above median its 10-year median of 36.00)
GF Value™: ¥19.02 vs. price of ¥14.28 (24.9% below fair value)
No single metric tells the full story. See the BJSE:920656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Chemsyn Pharm Co Ltd is engaged in Research, development, production and sales of veterinary drug raw materials, pharmaceutical raw materials and intermediates.
56GF Score
Get the complete analysis for BJSE:920656
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920656 has been successfully added to your 
